Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> FGFR

FGFR

FGFRs (fibroblast growth factor receptors) are transmembrane tyrosine kinase receptor. It is involved in carcinogenesis and plays an important role in cell differentiation, survival and proliferation etc.

Products for  FGFR

  1. Cat.No. Product Name Information
  2. GC62291 (Z)-Orantinib

    (Z)-SU6668; (Z)-TSU-68

     (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 ?M, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors. (Z)-Orantinib Chemical Structure
  3. GC33519 2,5-Dihydroxybenzoic acid

    Carboxyhydroquinone, 5-Hydroxysalicylic Acid, NSC 27224, NSC 49098, NSC 78825

     A benzoic acid with diverse biological activities 2,5-Dihydroxybenzoic acid Chemical Structure
  4. GC15801 ACTB-1003

    ACTB-1003

     ACTB-1003 (ACTB-1003) is an oral kinase inhibitor with IC50s of 6, 2 and 4 nM for FGFR1, VEGFR2 and Tie-2. ACTB-1003 Chemical Structure
  5. GC32127 Alofanib (RPT835)

    RPT835

     Alofanib (RPT835) (RPT835) is a potent and selective allosteric inhibitor of fibroblast growth factor receptor 2 (FGFR2). Alofanib (RPT835) Chemical Structure
  6. GC17283 AP26113

    Brigatinib

     AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113 Chemical Structure
  7. GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research. Aprutumab Chemical Structure
  8. GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity. ASP5878 Chemical Structure
  9. GC14005 AZD4547

    AZD 4547;AZD-4547

     FGFR inhibitor AZD4547 Chemical Structure
  10. GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. Bemarituzumab Chemical Structure
  11. GC10055 BGJ398

    Infigratinib, NVP-BGJ398

     An FGFR inhibitor BGJ398 Chemical Structure
  12. GC46924 BIBF 1120-13C-d3

    Nintedanib-13C-d3

     A neuropeptide with diverse biological activities BIBF 1120-13C-d3 Chemical Structure
  13. GC19075 BLU-554

    BLU-554

     BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling. BLU-554 Chemical Structure
  14. GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible BLU9931 Chemical Structure
  15. GC74046 BR-cpd7 BR-cpd7 is a PROTAC degrader for fibroblast growth factor receptor FGFR1/2 with DC50 of 10 nM. BR-cpd7 Chemical Structure
  16. GC73947 CEP-11981

    ESK981; BOL 303213X

     CEP-11981(ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI), which can target TIE2, VEGFR1-3 and FGFR1, and has potential anti-tumor and anti-angiogenic effects. CEP-11981 Chemical Structure
  17. GC10759 CH5183284 (Debio-1347)

    Debio 1347

     CH5183284 (Debio-1347) (Debio 1347) is an orally available and selective FGFR inhibitor with IC50s of 9.3, 7.6, and 22 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. CH5183284 (Debio-1347) Chemical Structure
  18. GC33352 CP-547632 A potent inhibitor of VEGFR2 and bFGF CP-547632 Chemical Structure
  19. GC38575 CP-547632 hydrochloride CP-547632 hydrochloride is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 hydrochloride is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 hydrochloride has antitumor efficacy. CP-547632 hydrochloride Chemical Structure
  20. GC60726 CP-547632 TFA CP-547632 TFA is an orally active, ATP-competitive and potent VEGFR-2 and FGF kinases inhibitor with IC50s of 11 nM and 9 nM, respectively. CP-547632 TFA is selective for VEGFR2 and bFGF over EGFR, PDGFRβ, and related tyrosine kinases (TKs). CP-547632 TFA has antitumor efficacy. CP-547632 TFA Chemical Structure
  21. GC62274 CPL304110 CPL304110 is a potent, orally active and selective inhibitor of fibroblast growth factor receptors FGFR (1-3), with IC50 values of 0.75 nM, 0.5 nM, and 3.05 nM for FGFR (1-3), respectively. CPL304110 Chemical Structure
  22. GC91419 CYY292 CYY292 is an inhibitor of PDGFRα, PDGFRβ, FGFR1, -2, and -3, (IC50s = 5.35, 4.6, 28, 28, and 78 nM, respectively). CYY292 Chemical Structure
  23. GC15217 Danusertib (PHA-739358)

    PHA-739358

     A pan-Aurora kinase and Abl inhibitor Danusertib (PHA-739358) Chemical Structure
  24. GC19399 Derazantinib

    ARQ 087

     Derazantinib is a novel, ATP competitive, small molecule, multi-kinase inhibitor with IC50 of 1.8nM for FGFR2, and 4.5nM for FGFR1 and 3. Derazantinib Chemical Structure
  25. GC13547 Dovitinib (TKI-258, CHIR-258)

    CHIR258, TKI-258

     Dovitinib (TKI-258, CHIR-258) (CHIR-258) is an orally active, potent multi-targeted tyrosine kinase (RTK) inhibitor with IC50s of 1, 2, 36, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, CSF-1R, FGFR1/FGFR3, VEGFR1/VEGFR2/VEGFR3 and PDGFRα/PDGFRβ, respectively. Dovitinib (TKI-258, CHIR-258) has potent antitumor activity. Dovitinib (TKI-258, CHIR-258) Chemical Structure
  26. GC32760 Dovitinib lactate (CHIR-258 lactate) Dovitinib lactate (CHIR-258 lactate) (TKI258 lactate) is a multi-targeted tyrosine kinase inhibitor with IC50s of 1, 2, 8/9, 10/13/8, 27/210 nM for FLT3, c-Kit, FGFR1/3, VEGFR1/2/3 and PDGFRα/β, respectively. Dovitinib lactate (CHIR-258 lactate) Chemical Structure
  27. GC12149 E-3810 E-3810 Chemical Structure
  28. GC69037 E7090

    E7090 is an effective selective FGFR inhibitor with oral activity, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM and 120 nM for FGFR1/FGFR2/FGFR3/FGFR4 respectively.

     E7090 Chemical Structure
  29. GC62696 E7090 succinate E7090 succinate is an orally available, selective and potent inhibitor of FGFR1, FGFR2 and FGFR3 tyrosine kinase activities, with IC50 values of 0.71 nM, 0.50 nM, 1.2 nM, and 120 nM for FGFR1/2/3/4, respectively. E7090 succinate Chemical Structure
  30. GC72468 Efruxifermin Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin Chemical Structure
  31. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  32. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  33. GC19142 Erdafitinib

    Erdafitinib

     A pan-FGFR tyrosine kinase inhibitor Erdafitinib Chemical Structure
  34. GC72413 Fazpilodemab Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody targeting fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab Chemical Structure
  35. GC63395 FGFR-IN-1 FGFR-IN-1 is a potent FGFR inhibitor with an IC50 of <100 nM for FGFR1, FGFR2, and FGFR3, respectively (patent US20130338134A1, example 219). FGFR-IN-1 Chemical Structure
  36. GC73608 FGFR1 inhibitor-10 FGFR1 inhibitor-10 (Compound 4i) is an FGFR1 inhibitor (IC50: 28 nM). FGFR1 inhibitor-10 Chemical Structure
  37. GC65212 FGFR1/DDR2 inhibitor 1 FGFR1/DDR2 inhibitor 1 is an orally active inhibitor of fibroblast growth factor receptor 1 (FGFR1) and discoindin domain receptor 2 (DDR2), with IC50 values of 31.1 nM and 3.2 nM, respectively. Antitumor activity. FGFR1/DDR2 inhibitor 1 Chemical Structure
  38. GC70914 FGFR2-IN-1 FGFR2-IN-1 is a selective FGFR2 inhibitor with an IC50 of 140 nM. FGFR2-IN-1 Chemical Structure
  39. GC64475 FGFR2-IN-2 FGFR2-IN-2 (Compound 38) is a selective FGFR2 inhibitor with IC50s of 389, 29, and 758 nM for FGFR1, FGFR2, and FGFR3, respectively. FGFR2-IN-2 Chemical Structure
  40. GC69106 FGFR3-IN-5

    FGFR3-IN-5 is an effective selective inhibitor of FGFR3, with IC50 values of 3, 44, and 289 nM for FGFR3, FGFR2, and FGFR1 respectively. It can be used in cancer research.

     FGFR3-IN-5 Chemical Structure
  41. GC19155 FGFR4-IN-1 FGFR4-IN-1 is a potent inhibiotr of FGFR4 with IC50 of 0.7 nM. FGFR4-IN-1 Chemical Structure
  42. GC62602 FGFR4-IN-5 FGFR4-IN-5 is a potent and selective covalent FGFR4 inhibitor with an IC50 of 6.5 nM. FGFR4-IN-5 exhibits strong anti-tumor activity in vivo and can be used for hepatocellular carcinoma research. FGFR4-IN-5 Chemical Structure
  43. GC50051 FIIN 1 hydrochloride

    FGFR irreversible inhibitor-1

     FIIN 1 hydrochloride is a potent, irreversible, selective FGFR inhibitor. FIIN 1 hydrochloride binds to FGFR1/2/3/4 and Flt1/4 with Kds of 2.8/6.9/5.4/120 nM and 32/120 nM respectively. The biochemical IC50s of FIIN 1 hydrochloride are 9.2, 6.2, 11.9, and 189 nM against FGFR1/2/3/4, respectively. FIIN 1 hydrochloride Chemical Structure
  44. GC17323 FIIN-2 Irreversible inhibitor of FGFR FIIN-2 Chemical Structure
  45. GC36044 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. FIIN-3 Chemical Structure
  46. GN10527 Formononetin

    Biochanin B, NSC 93360

     Formononetin is a potent FGFR2 inhibitor with an IC50 of 4.3μM. Formononetin potently inhibits angiogenesis and tumor growth. Formononetin Chemical Structure
  47. GN10540 Fumalic acid

    Coniferic Acid, 4-hydroxy-3-Methoxycinnamic Acid, NSC 2821, NSC 51986, NSC 674320

    A phenol with diverse biological activities.Natural product, extracted from ligusticum chuanxiong.

     Fumalic acid Chemical Structure
  48. GC64875 Gunagratinib

    ICP-192

     Gunagratinib (ICP-192) is a low toxicity and orally active pan-FGFR (fibroblast growth factor receptors) inhibitor that potently and selectively inhibits FGFR activities irreversibly by covalent binding. Gunagratinib can be used for the research of cancer. Gunagratinib Chemical Structure
  49. GC19187 H3B-6527 H3B-6527 (H3 Biomedicine) is a highly selective FGFR4 inhibitor with potent antitumour activity in FGF19 amplified cell lines and mice. H3B-6527 Chemical Structure
  50. GC30767 Heparan Sulfate

    Heparan sulfate (HS) is a complex, polyanionic polysaccharide ubiquitously expressed on cell surfaces and in the extracellular matrix.

     Heparan Sulfate Chemical Structure
  51. GC73852 Infigratinib-Boc Infigratinib-Boc is a derivative of Infigratinib containing a Boc (t-Butyloxy carbonyl) group. Infigratinib-Boc Chemical Structure
  52. GC73671 Irpagratinib

    ABSK011

     Irpagratinib (ABSK011) is an orally active inhibitor of fibroblast growth factor receptor (FGFR) tyrosine kinase, targeting to FGFR4 (IC50<10 nM). Irpagratinib Chemical Structure
  53. GC14592 KW 2449 A multi-kinase inhibitor KW 2449 Chemical Structure
  54. GC73276 LC-MB12 LC-MB12 is an orally active PROTAC compound targets FGFR2 degradation with a DC50 of 11.8 nM. LC-MB12 Chemical Structure
  55. GC15454 Lenvatinib (E7080)

    E-7080, ER-203492-00

     E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer.  Lenvatinib (E7080) Chemical Structure
  56. GC36438 Lenvatinib mesylate

    E-7080

     An inhibitor of VEGFR2 and VEGFR3 Lenvatinib mesylate Chemical Structure
  57. GC45754 Lenvatinib-d4

    E7080-d4

     A neuropeptide with diverse biological activities Lenvatinib-d4 Chemical Structure
  58. GC13848 LY2784544

    Gandotinib

     Potent inhibitor of JAK2 LY2784544 Chemical Structure
  59. GC13424 LY2874455

    LY 2874455; LY-2874455

     A pan-FGFR inhibitor LY2874455 Chemical Structure
  60. GC13410 Masitinib (AB1010)

    AB-1010, Masican, Masiviera

     Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib (AB1010) Chemical Structure
  61. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  62. GC65179 MAX-40279 MAX-40279 is a dual and potent inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 Chemical Structure
  63. GC49686 N-desmethyl Regorafenib N-oxide An active metabolite of regorafenib N-desmethyl Regorafenib N-oxide Chemical Structure
  64. GC11705 Nintedanib (BIBF 1120)

    Vargatef

     A VEGFR, FGFR, and PDGFR inhibitor Nintedanib (BIBF 1120) Chemical Structure
  65. GC36745 Nintedanib esylate

    Nintedanib

     Nintedanib esylate, as a kinase inhibitor, used for the treatment of non-small cell lung cancer suffered from first-pass metabolism which resulted in low oral bioavailability (~ 4.7%). Nintedanib esylate Chemical Structure
  66. GC16028 NVP-BGJ398 phosphate NVP-BGJ398 phosphate Chemical Structure
  67. GC64950 ODM-203 ODM-203 is an orally active and selective FGFR/VEGFR inhibitor with IC50 values of 6, 11, 16, 5, 9, 26 and 35 nM for FGFR3/1/2 and VEGFR3/2/1/4, respectively. ODM-203 has strong anti-tumour activity and activates immune responses in the tumour microenvironment. ODM-203 Chemical Structure
  68. GC16327 Pazopanib (GW-786034)

    GSK-VEG10003, GW786034B

     A multi-kinase inhibitor Pazopanib (GW-786034) Chemical Structure
  69. GC12730 Pazopanib Hydrochloride

    GW786034;Votrient;Armala;GW 786034;GW-786034

     VEGFR/PDGFR/FGFR/c-Kit/ c-Fms inhibitor Pazopanib Hydrochloride Chemical Structure
  70. GC72911 Pazopanib-13C,d3 hydrochloride

    GW786034-13C,d3 hydrochloride

     Pazopanib-13C,d3 (drochloride) is the deuterium and 13C labeled Pazopanib drochloride. Pazopanib-13C,d3 hydrochloride Chemical Structure
  71. GC44583 PD 089828

    EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor

     PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM). PD 089828 Chemical Structure
  72. GC12049 PD 161570 FGFR inhibitor PD 161570 Chemical Structure
  73. GC19279 PD-166866 PD166866 is a selective FGFR1 tyrosine kinase inhibitor with an IC50 of 52.4 nM. PD-166866 Chemical Structure
  74. GC17943 PD173074

    PD 173074,PD-173074

     PD173074 is an ATP-competitive FGFR1 and VEGFR2 inhibitor with an IC50 value of 26nM and 100-200nM, respectively, showing higher selectivity for FGFR1 over PDGFR and c-Src. PD173074 Chemical Structure
  75. GC32915 Pemigatinib

    INCB054828

     An FGFR inhibitor Pemigatinib Chemical Structure
  76. GC31495 PF-05231023

    Mal-PEG2-AZD

     PF-05231023 is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs. PF-05231023 Chemical Structure
  77. GC14396 Ponatinib (AP24534)

    AP 24534

     Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  78. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  79. GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values. PP58 Chemical Structure
  80. GC32802 PRN1371 An irreversible pan-FGFR inhibitor PRN1371 Chemical Structure
  81. GC72444 Recifercept Recifercept (TA-46) is a soluble, recombinant fibroblast growth factor receptor 3 (FGFR3) molecule. Recifercept Chemical Structure
  82. GC73674 Resigratinib

    KIN-3248

     Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor, with antineoplastic effect. Resigratinib Chemical Structure
  83. GC19154 Roblitinib

    Roblitinib

     Roblitinib (FGF-401) is a 1,8-naphthyridine pyridine derivative. Roblitinib Chemical Structure
  84. GC34067 Rogaratinib (BAY1163877) Rogaratinib (BAY1163877) (BAY1163877) is a potent and selective fibroblast growth factor receptor (FGFR) inhibitor. Rogaratinib (BAY1163877) Chemical Structure
  85. GC19317 S49076 S49076 is a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3 with IC50 values below 20 nM. S49076 Chemical Structure
  86. GC12776 SKLB610

    SKLB610; SKLB 610; SKLB-610

     An inhibitor of VEGFR2 SKLB610 Chemical Structure
  87. GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines. SM1-71 Chemical Structure
  88. GC10491 SSR128129E

    SSR

     allosteric inhibitor of FGFR1, orally-active SSR128129E Chemical Structure
  89. GC37679 SSR128129E free acid

    SSR free acid

     SSR128129E free acid is an orally available and allosteric FGFR inhibitor with an IC50 of 1.9 μM for FGFR1. SSR128129E free acid Chemical Structure
  90. GC14660 SU 5402 An inhibitor of VEGFR2, FGFR1, and PDGFRβ SU 5402 Chemical Structure
  91. GC61957 SU4984 SU4984 is a protein tyrosine kinase inhibitor, with an IC50 of 10-20 μM for fibroblast growth factor receptor 1 (FGFR1). SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor. SU4984 can be used for the research of cancer. SU4984 Chemical Structure
  92. GC32805 Sulfatinib (HMPL-012)

    HMPL-012

     Sulfatinib (HMPL-012) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC50s of in a range of 1 to 24 nM. Sulfatinib (HMPL-012) Chemical Structure
  93. GC19341 SUN11602 SUN11602 is a novel aniline compound with basic fibroblast growth factor-like activity. SUN11602 Chemical Structure
  94. GC49700 Takeda-6d Takeda-6d Chemical Structure
  95. GC19156 TAS-120

    TAS-120

     TAS-120 (TAS-120) is an orally bioavailable, highly selective, and irreversible FGFR inhibitor, with IC50s of 3.9, 1.3, 1.6, and 8.3 nM for FGFR 1-4, respectively. TAS-120 inhibits mutant and wild-type FGFR2 with similar IC50s (wild-type FGFR2=0.9nM; V5651=1-3nM; N550H=3.6nM; E566G=2.4nM). TAS-120 Chemical Structure
  96. GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Chemical Structure
  97. GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Hydrochloride Chemical Structure
  98. GC11622 TG 100801 TG 100801 Chemical Structure
  99. GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100801 Hydrochloride Chemical Structure
  100. GC16732 TSU-68 (SU6668,Orantinib)

    NSC 702827, Orantinib, TSU68

     TSU-68 (SU6668,Orantinib) (SU6668; TSU-68) is a multi-targeted receptor tyrosine kinase inhibitor with Kis of 2.1 μM, 8 nM and 1.2 μM for Flt-1, PDGFRβ and FGFR1, respectively. TSU-68 (SU6668,Orantinib) Chemical Structure
  101. GC34026 Tyrosine kinase-IN-1 Tyrosine kinase-IN-1 is a multi-targeted tyrosine kinase inhibitor with IC50s of 4, 20, 4, 2 nM for KDR, Flt-1, FGFR1 and PDGFRα, respectively. Tyrosine kinase-IN-1 Chemical Structure

Items 1 to 100 of 103 total

per page
  1. 1
  2. 2

Set Descending Direction